Despite a century of control and eradication campaigns, malaria remains one of the world's most devastating diseases. Our once-powerful therapeutic weapons are losing the war against the Plasmodium parasite, whose ability to rapidly develop and spread drug resistance hamper past and present malaria-control efforts. Finding new and effective treatments for malaria is now a top global health priority, fuelling an increase in funding and promoting open-source collaborations between researchers and pharmaceutical consortia around the world. The result of this is rapid advances in drug discovery approaches and technologies, with three major methods for antimalarial drug development emerging: (i) chemistry-based, (ii) target-based, and (iii) cell-based. Common to all three of these approaches is the unique ability of structural biology to inform and accelerate drug development. Where possible, SBDD (structure-based drug discovery) is a foundation for antimalarial drug development programmes, and has been invaluable to the development of a number of current pre-clinical and clinical candidates. However, as we expand our understanding of the malarial life cycle and mechanisms of resistance development, SBDD as a field must continue to evolve in order to develop compounds that adhere to the ideal characteristics for novel antimalarial therapeutics and to avoid high attrition rates pre-and post-clinic. In the present review, we aim to examine the contribution that SBDD has made to current antimalarial drug development efforts, covering hit discovery to lead optimization and prevention of parasite resistance. Finally, the potential for structural biology, particularly high-throughput structural genomics programmes, to identify future targets for drug discovery are discussed.
INTRODUCTION
There are few diseases of today's society that can claim the ancient origins owned by malaria, and yet it remains a major impact on world health. It was first described as a disease in China, 2500-2600 BCE [1] , but the parasite itself predates human existence; parasites within their mosquito hosts have been found preserved in amber from 30 million years ago [2] . The Plasmodium parasite that causes malaria was not discovered until 1880, and five species were subsequently described to infect and cause disease in humans: Plasmodium falciparum (Pf ), Plasmodium vivax (Pv), Plasmodium ovale, Plasmodium malariae (Pm) and Plasmodium knowlesi (Pk). Of these five species, P. falciparum causes the most deaths, whereas P. vivax is the most widespread.
Antimalarial treatments for malaria existed well before our understanding of the disease, and variations of these traditional medicines have continued as the basis for treatment until the present day. Since the 1600-1800s, extracts from bark of the cinchona tree, containing quinine, formed the primary treatment for malaria, and artemisinin, extracted from Artemisia annua, first described around 170 BCE was used to treat fever associated with malaria during the Ming Dynasty (1368-1644) [3] [4] [5] [6] [7] . Synthetic derivatives of these traditional medicines are still used clinically today, but the spread of resistant parasites has now rendered most of them ineffective.
Despite global health efforts to eradicate malaria, it remains a devastating disease. According to the most recent WHO (World Health Organization) World Malaria Report (2013), there were between 135 and 287 million cases of malaria in 2012 alone, and over half a million deaths resulted. The most effective treatment remains artemisinin-based combination therapy; however, the first reports of resistance to this class of drugs have arisen in SouthEast Asia [8] [9] [10] [11] . Alternative antimalarial drugs with a novel mechanism of action are desperately required, and the research community is exercising an arsenal of approaches in a global effort to achieve this goal.
Current methods for antimalarial drug discovery can be broadly classified into three major groups: (i) chemical modification of existing drugs, i.e. 'chemistry-based', (ii) rational targeting of essential parasite processes, i.e. 'target-based', or (iii) whole-cell phenotype screening for compounds that produce a desired effect on the whole cell of the parasite, i.e. 'cell-based'. These approaches have all been recently reviewed in detail [12, 13] . The chemistry-based strategy was primarily used during early antimalarial drug discovery efforts. Although some groups continue to use the approach with promise of success, current Abbreviations: ACP, acyl carrier protein; AMA1, apical membrane antigen 1; Apns, allophenylnorstatine; Cat, cathepsin; CG, cycloguanil; CQ, chloroquine; DHFR-TS, dihydrofolate reductase-thymidylate synthase; DHODH, dihydro-orotate dehydrogenase; DPAP1, dipeptidyl aminopeptidase 1; DXR, 1-deoxy-D-xyulose-5-phosphate reductoisomerase; Ec, Escherichia coli; ENR, enoyl-ACP reductase; FKBP35, FK506-binding protein 35; FP, falcipain; GGPP, geranylgeranyl diphosphate; GGPPS, geranylgeranyl diphosphate synthase; GSK3, glycogen synthase kinase 3; HAP, histoaspartic protease; HGXPRT, hypoxanthine-guanine-xanthine phosphoribosyltransferase; HMOA, 4-(2-hydroxy-4-methoxyphenyl)-4-oxobutanoic acid; Hp, Helicobacter pylori; HTS, high-throughput screening; lysRS, lysyl-tRNA synthetase; MEP, methylerythritol phosphate; MetAP, methionine aminopeptidase; MMV, Medicines for Malaria Venture; MTIP, MyoA tail-domain-interacting protein; MyoA, myosin A; NMT, N-myristoyltransferase; OMPDC, orotidine 5 -monophosphate decarboxylase; Pf , Plasmodium falciparum; Pk , Plasmodium knowlesi; Pm, Plasmodium malariae; PM, plasmepsin; PMT, phosphoethanolamine methyltransferase; PNP, purine nucleoside phosphorylase; PPIase, peptidylprolyl cis-trans isomerase; Pv, Plasmodium vivax; PYR, pyrimethamine; RON2, rhoptry neck protein 2; SAR, structure-activity relationship; SBDD, structure-based drug development; SUB1, subtilisin-like serine protease 1; Sym4, symplostatin 4; TMPK, thymidylate kinase; TrxR, thioredoxin reductase. 1 To whom correspondence should be addressed (email Sheena.mcgowan@monash.edu).
Figure 1 Malaria parasite life cycle
Mosquitoes cause infection by taking a blood meal (a). The female Anopheles mosquito introduces motile infective sporozoites into the bloodstream. The sporozoites migrate to the liver and infect hepatocytes (b). In the liver stage, the parasite reproduces asexually into a schizont (tissue schizogony), producing many merozoites (c). Rupture of the hepatocyte occurs and merozoites invade the bloodstream (d). The released merozoites infect red blood cells (d) where they undergo asexual reproduction (blood schizogony) (e) and develop into ring forms, trophozoites and schizonts, which in turn produce more merozoites. Lysis of the erythrocyte results in the repeat of the infective cycle. Some merozoites (f) will develop into gametocytes, which are the precursors of the sexual reproductive form called gametes. When gametocytes are taken up by a female mosquito (g), they mature in the mosquito gut (h) and sexual reproduction can proceed, continuing the life cycle. The life cycle targets of current and past clinical agents are indicated.
programmes have learned from our experience with other multidrug-resistant diseases such as hepatitis C and HIV, and now place an emphasis on structural mapping of drug-resistant targets to understand the mechanisms by which resistance develops and to pre-empt future parasite defences [14] [15] [16] [17] . Rational targets for drug discovery are typically selected based on genetic knockdown experiments demonstrating their essentiality to parasite viability. However, validation of the selected target as 'druggable' often requires potent lead compounds, which are generally not available at the onset of a drug discovery programme, and therefore require a number of iterations of inhibitor development before target validation can be achieved.
In an ideal scenario, inhibitor identification and optimization (guided by structural information where possible) subsequently results in novel lead compounds. The genome of P. falciparum was sequenced in 2002, and has allowed selection and validation of hundreds of novel molecular targets for screening and rational drug design; the wealth of potential antimalarial targets available have only begun to be explored (reviewed in [18] [19] [20] ). Perhaps the greatest impact on malarial drug discovery programmes has come from a collaborative approach to whole-cell HTS (high-throughput screening) that has occurred in recent years. Several large libraries have been screened and thousands of cell-active compounds have been identified and been made publicly available [21] [22] [23] (https://www.ebi.ac.uk/chemblntd; http://www.mmv.org/research-development). By screening against whole cells, compounds active during specific stages of the Plasmodium life cycle can be identified, whether they target single or multiple proteins, or indeed act via a nonproteinaceous target. Additionally, hit compounds progress with prior validation, and can progress without direct knowledge of the target or mechanism of action. This approach has proved successful for a number of current antimalarials in the development pipeline [12, 13] . The challenge of the cell-based approach develops when compound optimization stalls, and identification of the hit compounds' molecular targets for biochemical or structural analysis is necessary for further development from hit to lead. These three different methods of antimalarial drug discovery all benefit from the availability of structural information. High-quality structural information characterizing compound binding and inhibition mechanism is invaluable in the development of novel drugs, and imparts a substantial advantage on drug discovery programmes. We aim to review the role SBDD (structure-based drug development) plays in the development of novel antimalarial therapeutics, with a focus on current drug discovery programmes and potential new targets for SBDD.
MALARIAL LIFE CYCLE AND PROCESSES TARGETED IN DRUG DISCOVERY
The life cycle of the Plasmodium parasite involves a sexual stage in the Anopheles mosquito, wherein gametocytes ingested during a blood meal from a human host develop into sporozoites, and an asexual stage in humans, during which time these sporozoites enter first a liver and then erythrocyte phase of development, finally producing gametocytes which are passed on to a mosquito to complete the cycle (Figure 1 [24] . However, therapeutic targeting of the liver stage can interrupt transmission, and fewer hepatic forms of the parasite present an increased chance of achieving full prophylaxis and a decreased likelihood of resistance development [25] . Traditionally, compounds active during the liver stage of the Plasmodium life cycle have been difficult to identify. Previous research has greatly improved our understanding of the liver stage of the infection [26] , and wholecell assays are now able to screen for antimalarials active in this stage, together resulting in the characterization of novel liverstage targets [25] . We aim to overview the role that structural biology continues to play in the identification and development of potential antimalarial therapeutics targeting both the liver and erythrocyte stages of Plasmodium spp.
ANTIMALARIAL SBDD
Antimalarial drug targets can be classified according to their associated functional processes: (i) biosynthesis, (ii) membrane transport and signalling, and (iii) haemoglobin digestion. There are thousands of potential targets for antimalarial drug discovery, and hundreds of crystallographic and NMR structures of therapeutically relevant malarial proteins characterized. In the present review, we aim to overview currently active SBDD projects in which structural biology has provided significant contributions to the development of novel antimalarial compounds (chemical structures of a selection of compounds discussed are illustrated in Figure 2 ). We have also given particular focus to drug discovery programmes with validated molecular targets (i.e. current or pre-existing compounds with characterized activity against parasites either in culture or in animal models). The details of validation for the targets discussed are provided in Table 1 .
Biosynthesis

Fatty acid biosynthesis
Humans and Plasmodium use different pathways for fatty acid biosynthesis, the Fas-I and Fas-II pathways respectively. The Fas-II pathway in malarial parasites is essential for liver-stage development, thereby making the pathway an attractive target for therapeutics [27] [28] [29] . During the FAS-II pathway, the acyl substrate is covalently attached to ACP (acyl carrier protein) and shuttled between enzymes in repeated cycles of an elongation reaction (condensation, dehydration, reduction) [30] , supplying a number of proteins to target for disruption of the pathway.
FabZ (β-hydroxyacyl-acyl carrier protein dehydratase).
The third step in the Fas-II pathway of fatty acid biosynthesis is mediated by β-hydroxyacyl-acyl carrier protein dehydratase (FabZ), which catalyses the dehydration of β-hydroxyacylACPs to trans-2-enoyl-ACPs [31] [32] [33] . FabZ has been structurally explored as a drug target in Helicobacter pylori (Hp), wherein compounds block access to the active site by binding either adjacent to or within the tunnel defining the entrance to the site [34] . Crystal structures of Pf FabZ in active [35] and inactive forms [36] have been determined, and micromolar inhibitors (e.g. NAS91-11; Figure 2 ) active against both the enzyme and cultured P. falciparum identified [37] [38] [39] . Maity et al. [40] determined the structures of FabZ in complex with four such inhibitors, which, in contrast with inhibitors of HpFabZ, bind within the active site in a competitive manner. The bound inhibitors stabilize the substrate-binding loop, which is disordered in the structure of the References refer to work describing crystal structures of compounds in complex with targets (or if unavailable, compound identification). In order of appearance: FabZ, NAS91-11 [38] ; FabI, triclosan and triclosan-derivative (Compound 7) [48] ; DXR, fosmidomycin and fosmidomycin-derivative (Compound 5p) [62] ; PMT, sinefungin [78] ; HGXPRT, transition state analogue (Compound 3) [83] and product analogue (acyclic nucleoside phosphonate, Compound 17) [89] ; PNP, BCX4945 [101] ; OMPDC, HMOA [103] ; DHFR-TS, PYR and P218 [17] ; TMPK, thymidine analogue [113] ; dUTPase, nucleoside analogue (Compound 15a) [126] ; DHODH, DSM265 [127] and GENZ-668857 [132] ; SUB1, E683-0109 [156] ; GGPPS, BPH-811 [160] ; PMs, KNI-10395 [180] ; FPs, Compound 39 [189] and Sym4 [193] ; DPAP1, ML4118S [195] ; M1, BDM14471 [210] ; M1 and M17, CHR-2863 [212] ; GSK3, 3-amino-4-arylthieno [2,3-b] pyridines (5v) [222] ; FKBP-35, D44 [229] .
unliganded active form of the enzyme [35] . The architecture of the tunnel was mapped, and observed conformational changes in the active site used to suggest a mechanism by which FabZ can bind to substrate fatty acid chains of different lengths during catalysis. The ligand-bound structures additionally allowed a second inhibition mechanism to be identified. Flavonoid-based inhibitors were docked on to FabZ, and, similarly to the mechanism In vitro (P. falciparum 3D7, Palo Alto) Inhibits schizont parasite maturation [229] described for HpFabZ inhibition, were observed to bind at the entrance of the tunnel to the active site, blocking substrate access [34, 40, 41] .
ENR (enoyl-ACP-reductase) (FabI).
The broad-spectrum antibacterial and antifungal agent triclosan targets the final step in the Fas-II pathway, a reduction step catalysed by ENR (FabI), which is a validated antimalarial target in Plasmodium [42] . Triclosan ( Figure 2 ) and its derivatives are active against Plasmodium FabI, and crystal structures in complex with the enzyme determined their value as a lead series in the design of novel antimalarials [33, [43] [44] [45] [46] [47] [48] . The most recent of these used the crystal structure of FabI [43] to perform molecular modelling and docking studies to inform a scaffold hopping approach, replacing one of the lipophilic rings of triclosan with the chromenone functionality from coumarins ( Figure 2 ), natural compounds with a broad spectrum of activities and low toxicity [48, 49] . Crystal structures validated the approach, with the designed compounds binding similarly to triclosan, as predicted by docking experiments, while additionally illustrating new anchor points within the binding site and a structural route to a previously inaccessible hydrophobic groove. Additionally, the novel chemotype has dual enzyme activity, showing inhibitory potency against both Pf FabZ and Pf FabI, and antiplasmodial activity comparable with that of triclosan.
Isoprenoid synthesis
Two pathways exist for the synthesis of isoprenoids: the mevalonate pathway and methylerythritol [MEP (methylerythritol phosphate) or non-mevalonate] pathway [50] [51] [52] [53] . Plasmodium exclusively uses the MEP pathway, which is not found in mammals, making it an attractive target for antimalarial development [54] [55] [56] .
Fosmidomycin ( Figure 2 ) was identified as a cell-wall-inhibitory antibiotic in 1980, but the mode of action was not established until the discovery of DXR, the second enzyme in the MEP pathway, and the later finding that fosmidomycin is a potent inhibitor of the enzyme [57] . Clinical trials showed that fosmidomycin, when used alone or in combination with clindamycin, can be used to treat malaria. A poor pharmacokinetic profile, however, necessitated repeated high doses order to achieve acceptable cure rates [58] [59] [60] . Considerable research into the development of fosmidomycin derivatives to either improve potency or develop prodrugs [61] has been conducted, and the crystal structure of Escherichia coli (Ec) DXR was able to guide compound development. Although EcDXR has a high homology with Pf DXR in both the active site residues and the flexible loop that is important to ligand binding and catalysis, the E. coli form of the enzyme responds differently to compound substitutions [62] [63] [64] [65] . A breakthrough for these SBDD programmes arrived with elucidation of the crystal structure of Pf DXR bound to fosmidomycin [63] , and there has since been considerable structural investigation of compound binding to the P. falciparum enzyme [62, 66] . Pf DXR has a highly plastic active site, and demonstrates selectivity for specific ligand conformations, such as a cis arrangement of the hydroxamate oxygens of fosmidomycin [63] and S-configuration for α-phenylated fosmidomycin derivatives [66] . An elegant example of the benefits that accurate structural characterization confers to drug discovery programmes is provided by Xue et al. [62] , who combined the new Pf DXR structural information with the EcDXR SAR (structure-activity relationship) profile from an unrelated inhibitor series, and synthesized potent inhibitors of enzyme function and P. falciparum proliferation. The structure of one such inhibitor (fosmidomycin derivative; Figure 2 ) bound to Pf DXR, showed a novel mode of binding whereby the pyrimidine group induces a rearrangement of the flexible active site cover to generate an otherwise absent hydrophobic pocket.
Membrane biosynthesis
PMT (phosphoethanolamine methyltransferase).
Rapid synthesis of phospholipids, particularly phosphatidylcholine, is required for growth and replication of Plasmodium in human erythrocytes [67, 68] . Interfering with enzymes of the phospholipid synthetic pathway, such as PMT, which synthesizes the phosphatidylcholine precursor phosphocholine, negatively affect Plasmodium growth and survival [67] [68] [69] [70] [71] [72] [73] . Competitive inhibition of either substrate (phosphocholine) [72, 74, 75] or cofactor (S-adenosyl-L-methionine) [76] has been investigated, although the mechanism of action of PMT inhibitors amodiaquine, chloroquinine and primaquine remained unknown [74] . Lee et al. [77] determined the crystal structure of Pf PMT in complex with the inhibitory cofactor analogue sinefungin ( Figure 2 ), and found that, similarly to other methyltransferases, PMT has distinct and enclosed binding sites for both the substrate and cofactor. Although this suggests that major conformational changes must occur during catalysis, the binding pockets themselves show only very minor conformational rearrangement on ligand binding, and are intolerant to larger compound substitutions. The same group solved the structure of amodiaquine with Pf PMT [78] , whose binding had previously been mapped using NMR titration [74] , and found that, rather than competing with ligand binding, amodiaquine probably works by interfering with movement of the active-site lid domain. Computational docking of chloroquinine and primaquine to Pf PMT suggest that they bind similarly to amodiaquine and probably operate by the same allosteric means [78] . Amodiaquine, chloroquinine and primaquine are all weak binders and not specific for Plasmodium methyltransferases, therefore they are not potential clinical candidates. However, given their novel mode of inhibition, they may be valuable as starting points for further development. Most recently, the research group has screened for novel Pf PMT inhibitors, and, from the 11 compounds identified, characterized NSC-158011 as a competitive inhibitor of phosphoethanolamine (substrate), and a micromolar inhibitor of parasite intraerythrocytic asexual replication and gametocyte differentiation; however, no structural studies detailing compound binding have yet been described [79] .
Nucleic acid biosynthesis
Malarial parasites obtain nucleotides solely by de novo synthesis, in a pathway highly conserved among organisms, including humans [80] . However, unlike Plasmodium, humans also possess a salvage pathway, therefore awarding considerable interest to enzymes involved in malarial nucleotide synthesis. The antimalarial drugs PYR (pyrimethamine; Figure 2 ) and CG (cycloguanil) both interfere with de novo nucleotide synthesis, although widespread resistance to these drugs has now developed.
HGXPRT (6-oxopurine phosphoribosyl transferase; hypoxanthine-guanine-xanthine phosphoribosyltransferase). The synthesis of purine nucleoside monophosphates is required for DNA/RNA production, and the pathway has been validated for target in antimalarial drug discovery (for a review, see [81] ). Early transition-state analogues (immucillin 5 phosphates) are potent inhibitors, but bind both Plasmodium and human enzymes [82] , and the negatively charged phosphate group prevents cell permeation and is rapidly degraded [83] . Structures of the compounds with Pf HGXPRT [84] and human HGXPRT [85] showed that the phosphate group is important for binding, and allowed the design of compounds with a replacement phosphonate group attached to a simple acyclic scaffold [83] (Figure 2 ). The compounds made extensive interactions with active-site residues, catalytic magnesium and pyrophosphate molecules, and the catalytic loop. The phosphonate still prevented cell penetration; however, prodrugs designed to protect the negative charges with lysophospholipids were synthesized and resulted in compounds that block proliferation of P. falciparum in culture. The structure of Pf HGXPRT was vital in the development of this series of transition-state analogues; however, crystallization difficulties have prevented structural determination of the P. falciparum enzyme with any other inhibitor series [86, 87] . Instead, the structure of the human HGXPRT in complex with lead compounds has been used to feed SAR information into P. falciparum series [86] . Although these enzymes' SARs followed a similar profile, small structural differences were exploited to design selective inhibitors, and resulted in a new generation of compounds with a second phosphonate group (Figure 2 ), which succeeded in filling all three regions of the binding pocket [88, 89] . Subsequently, by applying known methods for prodrug synthesis of acyclic nucleotide phosphonates, nanomolar inhibition of Pf HGXPRT and arrest of parasitic growth was achieved [83, 90] . Although the compounds still demonstrate tight binding to the human enzyme, they have little cytostatic activity in mammalian cell lines, and structures with the human enzyme provide strategies to improve selectivity in future compound design.
PNP (purine nucleoside phosphorylase).
The transition-state structure of enzymatic reactions is a valuable tool in SBDD. Characterizing and mimicking the interactions evolutionarily designed to stabilize the high-energy transition state can result in highly potent inhibitors of the reaction. Such a method was used to develop the antimalarial agent BCX4945 [91, 92] , a transitionstate analogue of Pf PNP, which has recently entered pre-clinical trials. In Plasmodium, PNP is required for purine salvage and subsequent synthesis of nucleic acids, and its inhibition causes purine starvation and parasite death [93, 94] . Schramm and colleagues used detailed structural studies of Plasmodium, human and bovine PNP to investigate the hydrogen-bonding interactions responsible for defining the transition state [92, [95] [96] [97] [98] [99] [100] , and described a co-operative pattern for the P. falciparum enzyme in which disruption of a single bond destabilizes the entire network, resulting in substantially reduced binding affinity [92] . The inhibitor developed, DADMe-immucillin-G (BCX4945; Figure 2 ), is a picomolar inhibitor of Pf PNP, and has been shown to be active in a primate malaria model [101] . 
OMPDC (orotidine 5 -monophosphate decarboxylase)
. OM-PDC catalyses the final synthetic step of UMP in the de novo synthesis of pyrimidine nucleotides, and a correctly functioning enzyme is essential to P. falciparum survival. Crystal structures of Pf OMPDC in apo, substrate-and product-bound forms have been determined [102] , and used by Takashima et al. [103] for in silico screening to identify fragment binders. A combined Multiple Target Screening [104] and Docking Score Index [105] method was used, whereby docking affinity matrices are generated for each compound against multiple targets, candidates most selective for the target protein are chosen and chemically related compounds are subsequently selected. This approach identified 14 micromolar inhibitors of Pf OMPDC activity, and a crystal structure with one of the compounds, HMOA [4-(2-hydroxy-4-methoxyphenyl)-4-oxobutanoic acid; Figure 2 ] was determined. HMOA binds in the catalytic site with an aromatic ring occupying the phosphate-binding region of the pocket. Similarly to substrateand product-bound structures, the fragment stabilizes a flexible loop in the pocket, which is disordered in the apo structure, and additionally induces a structural change in a second active-site loop. The fragment-bound structure also showed that the regions of the pocket occupied by the substrate or product pyrimidine and ribose rings are unoccupied, and the authors suggest potential elaboration strategies to improve affinity and inhibition activity.
DHFR-TS (dihydrofolate reductase-thymidylate synthase).
In all known plant and protozoan species, the gene encoding dihydrofolate reductase (DHFR) and thymidylate synthase (TS) are fused to form a bifunctional enzyme DHFR-TS [106] , which recycles folates for use in thymidylate, purine and methionine synthesis; Pf DHFR-TS is one of the earliest targets for antimalarial SBDD [107] . Widespread use of PYR ( Figure 2 ) and CG, both of which target Pf DHFR-TS, has led to sitespecific mutations in the active site of the enzyme, rendering the drugs largely inactive. Current SBDD programmes now target the mutated versions of the enzyme, and use information of the restructured binding sites to design inhibitors with novel binding modes [17, 108] . Conformationally constrained ligands cannot adapt to changes in the geometry of the binding site, and are therefore susceptible to the development of resistance. In contrast, flexible inhibitors can avoid steric clashes with activesite mutations in the target enzyme, and therefore circumvent parasite resistance [109] . This concept was applied by Yuthavong et al. [17] , who designed compounds with a novel mode of inhibition using crystal structures of substrates and inhibitors in complex with wild-type Pf DHFR-TS, human DHFR and quadruple mutant Pf DHFR-TS (from PYR-and CG-resistant P. falciparum). The researchers identified 2,4-diaminopyridine as the minimally required active core of PYR and CG, and, using a flexible linker, joined this to a carboxy group to target a highly conserved arginine residue at the opposite end of the binding pocket (Figure 3a ). This arginine residue is required by Pf DHFR-TS to bind the folate substrate and is therefore likely to be resistant to mutation. Furthermore, it is surrounded by variant residues in the human form of the enzyme, which force a different, weaker, binding mode (Figures 3b and 3c) , thereby enabling the design of P. falciparum-selective inhibitors. The resultant compounds are subnanomolar inhibitors of both wild-type and quadruple-mutant Pf DHFR-TS, and possess antimalarial activity in vivo and in vitro. One of the compounds, P218 (Figure 2 ), has recently proceeded into pre-clinical development [MMV (Medicines for Malaria Venture) Research and Development]. Additionally, crystal structures showed that the compound series binds largely within the mapped 'substrate envelope' of the enzyme [16, 17] . This description is part of a strategy to prevent development of resistance learned from HIV-resistant SBDD, and predicts that mutation of residues within this region will have a detrimental effect on enzyme function and are therefore unlikely to occur [15, 110] .
TMPK (thymidylate kinase)
. TMPK, the enzyme that catalyses phosphorylation of TMP to TDP, has recently been suggested as a potential antimalarial target [111, 112] , and functional [113] and structural [112] characterization of the P. falciparum enzyme rapidly followed. The active site architecture of Pf TMPK and human TMPK are highly conserved, but key differences in the Ploop (substrate recognition) and LID domains (active-site cover) suggest that selective compounds could be designed [112] . Cui et al. [114] investigated selective inhibitors of the Mycobacterium tuberculosis TMPK [115] for activity against Pf TMPK, and found that α-thymidine analogues (Figure 2) show moderate activity and weak growth inhibition of cultured P. falciparum. Subsequent crystal structures of Pf TMPK in complex with inhibitors demonstrated that the thymidine ring mimics that of the TMP substrate, the deoxyribose ring acts to orient the thymidine into an enclosed region of the pocket, and bound water molecules illustrate potential regions to target in compound elaboration [113] .
dUTPase (deoxyuridine-5 -triphosphate nucleohydrolase).
Excess cellular dUTP becomes incorporated into DNA in place of dTTP, a mistake that later requires excision [116] . To prevent this, dUTPase catalyses the hydrolysis of dUTP to dUMP, which is subsequently used in the production of dTMP. In all organisms studied to date, dUTPase is essential for cell viability and is therefore an attractive drug target [117] [118] [119] [120] . In a traditional SBDD approach, specific Pf UTPase inhibitors were developed by derivitizing uridine with a trityl functionality to target a hydrophobic pocket not present in the human enzyme [121] [122] [123] . Subsequent crystal structures and in silico analyses have probed the P. falciparum and P. vivax active sites, and guided compound improvement in terms of potency, selectivity, cell efficacy, lipophilicity and size [121] [122] [123] [124] [125] [126] . Whereas modification of compound linkers gave modest improvements, crystal structures showed a lack of available interaction partners in the solvent-exposed region of the linker, limiting the potential of the series [125] . The same work showed that varying the nature of the trityl group (for example to trityloxy) improved antiplasmodial properties, probably by lowering compound lipophilicity and enhancing cell permeation, although high lipophilicity remains a serious drawback of the series. Molecular modelling into the Pf UTPase active site showed that, whereas two of the phenyl rings in the trityl group make favourable interactions with a key hydrophobic pocket, the third points to solvent and could be removed without detriment to compound selectivity; the resultant diphenyl derivatives (Figure 2) showed comparable activity and selectivity, improved solubility, and low micromolar P. falciparum growth inhibition [121, 122, 126] .
DHODH (dihydro-orotate dehydrogenase)
. The fourth step of the de novo pathway of pyrimidine biosynthesis, the oxidation of dihydro-orotate to orotic acid using FMN and ubiquinone (CoQ), is catalysed by DHODH, for which several known series of inhibitors exist [127] [128] [129] [130] [131] [132] [133] . The binding pockets of the P. falciparum and human enzyme are homologous and bind the same series of compounds, but small differences in sequence, structure and flexibility in the sites can confer selectivity. Indeed, Bedingfield et al. [134] showed that single substitutions of S-benzyltriazolopyrimidine-based compounds transfer the selectivity from human DHODH to Pf DHODH. Comparison of the first structures of Pf DHODH with bound inhibitors [131, 135] showed that the binding site has two regions: hydrophobic and hydrophilic. The hydrophobic pocket is flexible and demonstrates plasticity when bound to different series of inhibitors, whereas all known inhibitors overlap in the hydrophilic site [132] . A high-throughput screen for Pf DHODH inhibitors identified triazolopyrimidine as a hit compound [129] , and chemical modifications to improve metabolic stability resulted in in vivo active compounds, albeit at high doses [128, 136] . The structures of Pf DHODH bound to selected compounds in the series [127, 131] were solved, allowing characterization of their binding modes and identification of an unoccupied hydrophobic channel leading towards the FMN cofactor (indicated by an arrow in Figure 4a ). Taking into account the potential for flexibility in the binding site of Pf DHODH [131] , the compounds were elaborated with unbranched lipophilic substituents, which as predicted, formed additional van der Waals interactions with the channel, while conserving the key interactions of the compound core, and demonstrated nanomolar growth inhibition of cultured P. falciparum, reasonable metabolic stability and in vivo activity [127] . The lead compound from the series, DSM265 (Figure 2 ), has demonstrated excellent preclinical safety and pharmacokinetic profiles in animals, and has proceeded on to Phase I clinical trials (MMV Research and Development).
In a separate study, Patel et al. [133] described a HTS that identified N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides as cell-active inhibitors of Pf DHODH. A medicinal chemistry campaign [132] improved compound activity and selectivity, and investigated the compounds as a pan-species series of inhibitors by assessing their activity against PbDHODH and PvDHODH. Compound-binding modes to both human DHODH and Pf DHODH were structurally characterized, combined with published structural information from other projects and used to reconcile potency and selectivity data. This characterization determined that compounds docked into an adjacent hydrophobic pocket that is inaccessible to the triazolopyrimidine compounds, despite the fact that the compounds occupy the same space and make similar hydrogen-bonding interactions in the hydrophilic site (Figures 4b and 4c) . Two of the compounds from this series (GENZ-669178 and GENZ-668857, Figure 2 ) demonstrate nanomolar activity against Pf DHODH and cultured P. falciparum (although weaker activity against P. berghei and P. vivax was also reported), are active in murine models, have low human toxicity, are metabolically stable and are candidates for pre-clinical studies.
Protein modification
NMT (N-myristoyltransferase).
NMT was identified as a promising drug target for protozoan parasites in 2008 [137] and has since been established as a target for antimalarial SBDD. It is a ubiquitous eukaryotic enzyme that catalyses the covalent attachment of myristate to target proteins; myristoylated proteins are critical for parasite viability, and NMT is critical for the survival of P. falciparum. Selective inhibition of Plasmodium NMT is required over the two human isoforms, NMT1 and NMT2, although sequence homology in the active sites necessitate the use of structural information in inhibitor design [138] . The first structure of a Plasmodium NMT (PvNMT) was solved with a HTS hit (MRT00057965) and a non-hydrolysable myristoylCoA analogue, which showed the β-sheet structure twisted to present a putative substrate-binding groove and bound inhibitor [139] . Compound elaboration based on the structure resulted in improved selectivity over the human isoforms, but did not result in any improvement to the micromolar inhibitory activity against PvNMT. Yu et al. [140] took a different approach to inhibitor discovery and screened known inhibitors of NMT from other organisms, from which they identified a benzofuranbased compound as a starting point for elaboration. Structural studies then used PvNMT, wherein the inhibitory compounds are enclosed within the peptide-binding pocket, to inform elaboration of Pf NMT inhibitors, and resulted in compounds that fortuitously inhibited both, and suggested that effective panspecies inhibitors could be developed. Chemical modification had little effect on either the structure of the active site or the binding position; improved activity was achieved by optimizing linkers to subtly orient an aromatic group into a tight pocket and targeting a flexible active-site histidine residue, modifications which conferred selective micromolar P. falciparum activity.
Comparison of compound-bound PvNMT, human NMT1 and human NMT2 structures identified a tyrosine residue that is crucial to compound binding in all structures, but undergoes a conformational change on compound binding to the human isoforms. The energy required for the conformational change to accommodate the compounds in the human enzymes could account for the selectivity of the series. The compound series was developed further [141] , and improved ligand efficiency was achieved by replacing the benzo[b]furan with benzo[b]thiophene. Although this substitution improved Pf NMT inhibitory and antiparasitic activity, modifications to exploit an active-site serine residue by replacing the ethyl ester with a methoxyphenyl resulted in loss of selectivity over human NMT1. The structure of this compound bound to PvNMT showed that the compound adopted a different binding mode from that of the parent compound, with the scaffold sitting deeper within a hydrophobic pocket. In this position, the methoxyphenyl makes no favourable interactions, and adopts multiple binding modes, thereby explicitly directing future compound development. Further research guided by ligand-bound structures and a 'ligand-efficiency-dependent liphophilicity score', which describes affinity, lipophilicity and molecular mass, resulted in the most potent Pf NMT and PvNMT inhibitor described to date, with adequate selectivity over human NMTs [142] . This compound was used to validate NMT as an antimalarial target in vitro and in vivo, demonstrating that selective inhibition of NMT results in an inability of parasites to form the inner membrane complex and parasite cell death [143] .
Membrane transport and signalling
MyoA (myosin A) interaction with MTIP (MyoA tail-domain-interacting protein)
The interaction between MyoA and MTIP is a crucial part of the invasion machinery of all three invasive forms of the malarial parasite (sporozoite, merozoite and ookinete), and is highly conserved across all Plasmodium spp. SBDD programmes targeting the interaction in the design of novel antimalarials were initiated by crystal structures of the complex between MTIP and the MyoA tail, showing that the helical MyoA tail can bind both open and closed forms of MTIP [144, 145] (Figures 5a and 5b) . The binding pocket on MTIP is therefore a highly adaptable and deep hydrophobic groove. Kortagere et al. [146] designed a pharmacophore model of the P. falciparum MTIP-binding pocket based on the open PkMTIP-PyMyoA-tail crystal structure [144] , and used a hybrid structure-based virtual screening approach [147] to discover pyrazole/urea-based compounds that inhibit the interaction with submicromolar activity. Docking studies were used to characterize the mode of binding of the small molecules to MTIP and to guide the design of 51 novel compounds into three distinct regions of the binding pocket (Figure 5c ), optimizing for linker length and hydrophobic interactions. This method resulted in a series of compounds demonstrating nanomolar inhibition of parasite growth and one compound that inhibited gliding motility of parasites. However, the hydrophobic nature of the compounds makes them unsuitable for use as therapeutics, and the series therefore requires further development.
AMA1 (apical membrane antigen 1) interaction with RON2 (rhoptry neck protein 2)
AMA1 is a type 1 integral membrane protein that interacts with its (parasite-derived) protein receptor, RON2. The AMA1-RON2 interaction is an essential component of the moving junction that drives host cell invasion [148] . Interference with this proteinprotein interaction by targeting either AMA1 or RON2 is a new approach for the design of invasion inhibitors [149] . The RON2-binding site on mature AMA1 is formed though close association of two PAN domains that form a highly conserved hydrophobic cleft [150] . The essential function and conserved nature of this hydrophobic groove make it an attractive target for pan-species inhibitors and also other apicomplexa infections that utilize a similar mechanism for invasion [149] . Mapping of the hydrophobic groove has been achieved via NMR [151] and crystallography [152] , and show that invasion-inhibitory peptides mimic the interaction of the RON2 substrate. Srinivasan et al. [153] recently used the AlphaScreen assay to identify potential small-molecule inhibitors of the AMA1-RON2 interaction. Six compounds containing a benzopyrimidine or benzoimidazole-like functional core and an extended aromatic group blocked invasion of three P. falciparum clones. Proof-of-concept optimization of a pyrrolo-pyrimidine core improved the potency of analogues to low-micromolar levels in invasion assays. SPR (surface plasmon resonance) and depletion assays were used to confirm that AMA1 was the target of the small molecules, and molecular docking within the hydrophobic cleft suggested two potential interaction sites for the compounds [153] . The atomic detail and binding mode of these small molecules remains to be determined and would open the door to SBDD approaches.
SUB1 (subtilisin-like serine protease 1)
SUB1 plays an essential role in the cascade of proteolytic events that co-ordinates the egress of merozoites and their subsequent entry into erythrocytes (reviewed in [154, 155] ). In the absence of a crystal structure of SUB1, molecular modelling of the P. falciparum and P. vivax SUB1 enzymes has delivered potent protease inhibitors [156, 157] . The active site of P. falciparum, P. vivax and P. berghei SUB1 has conserved S1-S4 subsites [157] . The pockets show a polar nature at S1, a restricted S2 and a nonpolar S4. Furthermore, and unusually, prime-side interactions also play an important role in substrate binding, increasing the target pharmacophore. Withers-Martinez et al. [157] translated their substrate mapping to generate a broad-spectrum inhibitor of the Plasmodium SUB1 proteases. KS-644 is a peptidyl α-ketoamide which possesses a prime-side carboxy moiety designed to mimic a natural substrate. The activity against parasites was modest and was attributed to a lack of good membrane permeability properties due to the charged nature of the compound. In an in silico campaign, Bouillon et al. [156] used homology models of PvSUB1 to virtually screen the ChemDiv library using the FlexX, FlexX-Pharm and ICM packages. Experimental validation of selected hits identified ChemDiv E683-0109 ( Figure 2) as (i) a cross-inhibitor of recombinant SUB1 from P. vivax, P. falciparum and P. berghei, (ii) a potent anti-P. falciparum agent (nanomolar EC 50 ), and (iii) an inhibitor of P. falciparum egress and subsequent rupture [156] . E683-0109 has a central quinolone group with an indole moiety that interacts with the backbone of the S4 subsite and a paramethoxyaniline that forms three hydrogen bonds within the S1 pocket. These studies pave the way forward for a panspecies protease inhibitor that controls invasion or rupture.
GGPPS (geranylgeranyl diphosphate synthase)
The MEP pathway provides GGPP (geranylgeranyl diphosphate) that is used to prenylate proteins to facilitate their anchor in the membrane. GGPP is synthesized by GGPPS [158, 159] . To target prenyl synthesis for the development of novel antimalarial compounds, No et al. [160] used a cell-based P. falciparum growth inhibition assay to screen a focused library containing a large representation of bisphosphonates, a known class of GGPPS inhibitors [161, 162] . Hit compounds included lipophilic derivatives of zoledronate and risedronate, bisphosphonate bone-resorption drugs that inhibit human farnesyl diphosphate synthase, whose function is combined with bifunctional GGPPS in the Plasmodium MEP pathway [161] . Zoledronate and risedronate themselves inhibit Pf GGPPS, and crystal structures of the compounds bound to PvGGPPS are available, but poor cell penetration renders them inactive in cell assays [161] [162] [163] . To confirm binding of the novel leads (BPH-703 and BPH-811; Figure 2) to GGPPS, the crystal structures in complex with PvGGPPS were determined [160] . Whereas the polar headgroup of compounds bind similarly to their more lipophilic parent compounds, their alkyl tails occupy a hydrophobic tunnel inaccessible in the human enzyme (and therefore not accessed by zoledronate and risedronate), spanning both molecules of the PvGGPPS dimer. The alkyl substituents expected to merely improve cell penetration are likely to be important contributors to binding affinity, and resulted in potent compounds with in vitro and in vivo activity.
Haemoglobin digestion
Proteases involved in host-cell haemoglobin digestion have become the focus of many SBDD campaigns. Haemoglobin is processed into individual amino acids, which are used for parasite protein synthesis. Haemoglobin hydrolysis involves a complicated proteolytic cascade that utilizes cysteine, aspartic and metallo-proteases. Proteases are attractive targets for SBDD purposes as they (i) have a defined active site amenable to binding of small-molecule inhibitors, and (ii) may possess allosteric sites that can aid selectivity in SBDD initiatives [164] . It is estimated that proteases represent 5-10 % of all pharmaceutical targets being pursued for drug development. Furthermore, homologous proteases often function as key enzymes in other organisms and, as such, SAR can often inform projects on related targets and therefore be relevant to a wide range of diseases.
Plasmepsins and an HAP (histo-aspartic protease)
The PM (plasmepsin) I, II and IV and an HAP (known in the early literature as PMIII) are involved in the initial steps of haemoglobin digestion [165, 166] . The PM enzymes belong to the pepsin-like family of aspartic proteases and their sequences are highly homologous [166] . Similarly to other pepsin-like aspartic proteases, the active sites of PM1, PMII and PMIV include two crucial aspartic acid residues, Asp 32 and Asp 215 (numbered as per standard nomenclature for mammalian pepsin), whereas Asp 32 is replaced by histidine in HAP [167] . The aspartate residues are bridged by a water molecule, which provides the proton for nucleophilic attack of the scissile bond. The PMs are potently inhibited by pepstatin A [168] . Early rational drug design efforts using peptidomimetic inhibitors indicated that the individual PM enzymes appeared to have low druggability, as high inhibitory potency was generally coupled with low selectivity against the closely related human CatD (cathepsin D) and relatively poor activity against parasites [169] . Previous biological data reveal a functional redundancy in the PMs, suggesting that multiple PMs must be targeted to produce potent antiparasitic effects [170] . SBDD, guided by recent crystal structures and familial active-site similarities, has suggested the possibility that a broad-spectrum PM inhibitor might be possible. Combinatorial chemistry has produced libraries that can fingerprint the substrate specificity of the PMs. Liu et al. [171, 172] used an iterative process to determine specificities at each of the sub and sub-prime pockets of Pf PMI, and the favoured amino acids at each position were introduced to a selective peptidomimetic inhibitor, containing a reduced methylene-amino [-CH 2 -NH-] between the P1 and P1 [172] . The designer compound showed nanomolar inhibition of PMI and a 5-fold selectivity over human CatD, and was used to determine the co-crystal structure in complex with PMII. Extending the process to each of the PMs produced similarly potent compounds against their target PM, but also providing cross-inhibition of the other family members [172] . Molecular docking of the peptides into existing crystal structures of PMI, PMII and PMIV identified conserved binding poses, analogous to that observed in the cocrystal structure, for all of the designed peptides.
Over the last 20 years, extensive SAR knowledge has been gained using Apns (allophenylnorstatine)-based compounds as transition-state analogues to target the PM enzymes. More recently, the KNI series of compounds, developed initially to target HIV-1 protease [173] , have been investigated as PM inhibitors. The KNI compounds contain a central core of an Apns moiety followed by a thioproline ring. This series was shown to have good bioavailability and low toxicity [174] . Four crystal structures of KNIs bound to PMs have been determined: PMIV-KNI-764, PMI-KNI-10006, HAP-KNI-10006 and HAP-KNI-10395. The structures show that, although each KNI compound is a potent inhibitor of the PMs, their interaction with the active site is non-traditional and also variable, depending on the PM [175] . The low-resolution structure of KNI-764 bound to PmPMIV showed that the inhibitor bound in an unexpected binding orientation with Apns occupying the S1 pocket [176] . The P2 group was found outside the S2 pocket, wedged between the flap and a loop [176] . Design and synthesis of KNI-1006 incorporated aromatic groups at positions P1, P2 and P2 , and these groups were joined by rotatable bonds to the core of the inhibitor to improve the broad-spectrum specificity [177] . This approach was successful and KNI-1006 showed subnanomolar affinity (IC 50 ) for each PM in vitro [177] . The low-resolution structures of PMI and HAP bound to KNI-10006 also showed that KNI-1006 bound in the opposite orientation to that found of other peptidic inhibitors of aspartic proteases [178, 179] . However, the mode of binding of KNI-10006 to PMI was substantially different to that of HAP. KNI-1006 is bound to the active site of PMI in an extended conformation (Figure 6a ), similar to KNI-764 in PMIV. In PMI-KNI-10006 and PMIV-KNI-764, the central hydroxy group is bound between the catalytic dyad. However, in the HAP-KNI-10006 structure, the presence of the catalytic histidine residue causes the hydroxy core to point away from the catalytic residues [179] (Figure 6b) . Furthermore, the 2,6-dimethylphenyloxyacetyl moiety of KNI-10006 is bound to the flap pocket in HAP [179] . The flap is found in an open conformation in HAP-KNI-10006 but a closed conformation in PMI-KNI-10006 [179] . The addition of an N-terminal phenyl acetyl group to KNI-10006 resulted in KNI-10395 (Figure 2 ) that was a potent in vitro inhibitor of HAP (and other PMs) and the co-crystal structure of HAP-KNI-10395 of higher resolution was obtained [180] . Unexpectedly, in this structure, HAP formed a domain-swapped dimer and had the KNI compound bound in a previously unobserved conformation (Figure 6c ). The flap pocket that bound the 2,6-dimethylphenyloxyacetyl moiety in KNI-1006 was instead occupied by a loop from the dimeric HAP partner. Furthermore, the aminoindanol moiety had reduced interactions with the HAP active site owing to the crossover region of the domain-swapped dimer [180] . The ability of the KNI series to adapt their binding modes and conformations to suit the active-site architecture of the individual enzymes makes them attractive candidates for optimization; however, to date, their efficacy against P. falciparum-infected erythrocytes has been modest and does not reflect the potency of the in vitro assays.
Recent work has identified other non-peptidomimetic scaffolds capable of inhibiting the PMs. Aureggi et al. [181] used a highly decorated 7-azabicyclo[2.2.1]heptane core to target the central catalytic dyad through ion pairing and ionic hydrogen-bonding. Molecular modelling indicated that addition of 3-substituents would allow the compound to occupy the flap pocket, S1/S3 and S1 pockets. Synthesis and determination of the compound inhibitory activities validated the approach, with selective (over human CatD) nanomolar inhibition of PMI, II and IV achieved [181] . The efficacy of these compounds against parasites remains to be determined. The vast structural data available to the PM field also produced a rationally designed virtual screening protocol that identified 15 novel small-molecule inhibitors of the PM enzymes that were also active against P. falciparum [182] . The authors of this study state that these new compound scaffolds can now enter a SBDD pipeline.
Falcipains
After the PM aspartyl proteases carry out the first cleavage of the haemoglobin into two peptide chains, papain-like cysteine proteases called falcipains (FPs) digest these chains into smaller peptides. The P. falciparum genome encodes four FPs: FP1, FP2, FP2 and FP3. FP1 has been shown to be non-essential for parasite development and its precise biological role remains unknown [183] . FP2 and FP3 both contribute to haemoglobin digestion and must be simultaneously inhibited to achieve parasite death [184] . FP2 shares 93 % identity with FP2 and is thought to be a result of gene duplication of FP2. The first crystal structures of the FPs were of FP2 bound to the inhibitors cystatin [185] and expoxysuccinate E64 [186] , and FP3 bound to the aldehyde leupeptin [186] . The structures showed that the smallmolecule inhibitors were largely targeting the S2 and S3 subsites in both FP2 and FP3. A large body of SARs for irreversible peptidyl-based inhibitors has been produced, including vinyl sulfones, vinyl sulfone esters and vinyl sulfonamides (reviewed recently in [187, 188] ). The peptidyl-based compounds inhibit enzymatic activity in the low-nanomolar range, but appear susceptible to protease degradation and poor absorption. For this reason, peptidyl mimetics and non-peptidic inhibitors have been investigated extensively as FP inhibitors (reviewed in [187, 188] ). Very recently, a series of α-keto-substituted peptidomimetics used a combination of the X-ray crystal structures of FPs and cruzain, a related cysteine protease, to design a series of novel peptidomimetics targeting FP2 and FP3 [189] . Analysis of the series identified compound 39 ( Figure 2) as the most potent [FP inhibition in the nanomolar range and low-micromolar activity against CQ (chloroquine)-resistant P. falciparum strain]. Weldon et al. [189] subsequently employed structural and computational techniques to understand the SAR of the compounds and ascertained that design efforts need to consider hydration stability of R-group positions in chemotypes. The extensive body of SARs, X-ray crystal structures and inhibitory chemotypes now available provide the ideal basis for SBDD campaigns to deliver potent therapeutics targeting the FPs.
A new direction in FP inhibition is the use of natural products as a starting block for SBDD initiatives. In 2009, two independent groups showed that cyanobacterial metabolites Sym4 (symplostatin 4) ( Figure 2) and GallA (gallinamide A) demonstrate potent antimalarial activity [190] [191] [192] . Treatment of P. falciparum-infected erythrocytes with Sym4 resulted in a swollen food vacuole, a phenotype indicative of haemoglobin protease inhibition [193] . Stolze et al. [193] confirmed that Sym4 was indeed a FP inhibitor and that the methyl-methoxypyrrolinone group was responsible for the antimalarial activity.
DPAP1 (dipeptidyl aminopeptidase 1)
DPAP1 is essential to parasite development and contributes to haemoglobin digestion [194] . The protease cleaves dipeptides from the N-terminus of oligopeptides. Inhibition of DPAP1 with peptidic inhibitors impaired parasite development, but the compounds were not stable in mouse serum [195] . There is currently no structure of DPAP1 available; however, the use of a homology model of the protease (based on the closely related human CatC) allowed the design of novel non-peptidic inhibitors of DPAP1 that were more stable in mouse serum and decreased mouse parasitaemia [195] . DPAP1 remains a new and exciting drug target, as inhibitors of DPAP1 are active against parasites at both the asexual and sexual stages [196] , creating the possibility of a dual-stage drug that can treat patients and block transmission.
Metallo-aminopeptidases
The last step in the haemoglobin digestion proteolytic cascade relies on the activity of metallo-aminopeptidases, including the neutral aminopeptidases M1 and M17, and the M18 aminopeptidase [166, [197] [198] [199] . The metallo-aminopeptidases are hypothesized to work in concert to facilitate the final stages of haemoglobin digestion. The Pf M1 enzyme has been shown to be responsible for the final stages of haemoglobin digestion [200] . In contrast, Pf M17 may have additional function(s) to haemoglobin digestion since specific inhibition of its activity in P. falciparum parasite cultures causes growth retardation early in the erythrocytic life cycle, before haemoglobin digestion is initiated [200, 201] . M18 appears to be non-essential for bloodstage replication, but contributes to parasite fitness [197, 202] . The absolute requirement of aminopeptidases to parasites for complete haemoglobin digestion makes this process an ideal target for chemotherapeutic intervention. Furthermore, the essential role of M17 early in the life cycle has added value as a therapeutic target as it may prevent blood-stage infection. Agents that inhibit the activity of the M1 and M17 neutral aminopeptidases in parasites have been shown to control both P. falciparum laboratory and P. chaubaudi chaubaudi murine models of malaria [203] [204] [205] . Similarly, the enzymes are highly conserved among all Plasmodium species, indicating that future therapeutics could deliver cross-species inhibition. To date, inhibitors of M1 and M17 have targeted the active sites of the enzymes and recent inhibitor scaffolds described include phosphonopeptides [203, 204, 206, 207] , peptide-based bestatin and analogues [200, 203, 204, 208, 209] , and hydroxamate derivatives [210, 211] . The inhibitor scaffolds all act to chelate the essential zinc ions and mimic the transition state of the molecule. SBDD has been driving the development of novel M1 and dual M1/17 inhibitors in recent years. Velmourougane et al. [209] identified a key feature of the M1 active site when they showed that the S1 pocket is capable of substantial inhibitorinduced rearrangement due to the presence of a flexible polar glutamic acid (Glu 572 ) in the pocket (Figure 7 ). This flexibility has implications for the size and shape of the M1 pharmacophore. A library of arginine and homoarginine derivatives identified that Val 459 is also able to accommodate inhibitor-induced alterations to the pocket size and shape, and identified 4-(1H-pyrazol-1-yl)phenyl)(amino)methylphosphonic acid as an exciting lead for further development of a dual M1/M17 inhibitor [206] (Figure 7) . Immediate strategies include the removal of the phosphonic acid moiety to improve cell permeability and the overall pharmokinetic profile [206] .
The intracellular location of the neutral aminopeptidases represents a significant challenge for drug design and delivery; however, recent advances show that compounds can be delivered to the site of action. An orally bioavailable hydroxamatecontaining ester, CHR-2863 (Figure 2) , has been shown to be efficacious against murine malaria (P. chaubaudi chaubaudi) [212] . The compound is, however, a close relative of tosedostat, a potent inhibitor of a number of intracellular mammalian aminopeptidases [212] . In a separate study, a malonohydroxamic lead compound BDM14471 (Figure 2) , with good physicochemical properties, in vitro plasma stability and promising antiplasmodial activity in vitro, was assessed in mice using the malaria strain P. berghei [210] . The in vivo results did not match the potency noted in vitro and Deprez-Poulain et al. [210] conceded that the compound may be trapped in the red blood cells and unable to enter the parasite.
The X-ray crystal structure of the M18 aminopeptidase was determined and showed that the enzyme forms a large dodecameric structure with a highly restricted specificity [213] . Very few small-molecule inhibitors of M18 exist; however, a probe report from the NIH Molecular Libraries programme reports the results of an HTS campaign to identify small-molecule inhibitors of M18 and in combination with the structure opens a new avenue for M18 SBDD [214] .
Unknown/range of functions
GSK3 (glycogen synthase kinase 3)
Kinases are drug targets for a wide range of clinical conditions, and have been validated as therapeutic targets for antimalarials [215, 216] . Although the function of GSK3 is unknown, it is essential to the asexual erythrocytic cycle and inhibition of its activity suppresses erythrocytic parasitaemia in vitro [217] [218] [219] . High interspecies homology is a known disadvantage of kinases as therapeutic targets, but a bioinformatic comparison of the ATPbinding site of Pf GSK3 to the human homologue suggested that selective chemotypes could be identified [220, 221] . HTS using a kinase-targeted library followed by similarity searches for structurally related inhibitors identified the 3,6-diamino-4-(2-halophenyl)-2-benzoylthieno[2,3-b]pyridine-5-carbonitrile motif as a Pf GSK3 inhibitor. Subsequent SAR analysis showed that variation of the substitution pattern could confer selectivity over the human orthologue, and a selective series was generated [222] . In the absence of a Pf GSK3 crystal structure, a human GSK3 structure in complex with a related compound was determined, and used to inform docking of the P. falciparum-specific inhibitors into a Pf GSK3 homology model [220, 222] . As predicted, the compounds bound in the ATP-binding pocket, but a different hydrogen-bonding network compared with the human counterpart allowed rotation of the core and orientation of a thiophene sulfur towards the key 'gatekeeper' methionine [222] . The lead series of compounds have micromolar enzyme and antiplasmodial activity, and demonstrate selectivity for Plasmodium GSK3 over kinases of other species (including humans).
FKBP35 (FK506-binding protein 35)
FK506, a human immunosuppressant, demonstrates antimalarial activity [223, 224] , making it a candidate for the targethopping approach of drug discovery, whereby known drugs with activity against other targets are used as starting points for drug development. The mechanism of antimalarial activity was traced to the Plasmodium form of FKBP35, a member of the immunophilin family, which primarily acts as a PPIase (peptidylprolyl cis-trans isomerase) in protein folding [225] , but also performs a number of roles in mediating cellular responses. The crystal structures of Pf FKBP35 and PvFKBP35 were solved unliganded, in complex with their peptide substrates or bound to FK506 [226] [227] [228] , and were used to map the active-site architecture and inform an in silico screen [229] . The screen identified D44, which was found to be a nanomolar inhibitor of both Pf FKBP35 and PvFKBP35 PPIase activity, acted selectively over the human counterpart, and inhibited P. falciparum growth by interfering with schizont parasite maturation. A hit from a structure-guided in silico screen was therefore used to validate FKBP35 as an antimalarial target, and the crystal structure of the compound determined in complex with Pf FKBP35 and PvFKBP35 will allow the next generation of inhibitors to be designed [229] .
THE FUTURE OF ANTIMALARIAL SBDD
New structures of antimalarial targets
Although the three-dimensional structure of a target protein is capable of rapidly accelerating the optimization of lead compounds, it is not always available. Additionally, it is not always easy to determine; X-ray crystallography still suffers from bottlenecks in protein crystallization, particularly of membranebound or integral membrane proteins, and parasite proteins are often difficult to express. In these cases, SAR information derived from medicinal chemistry campaigns provide the main driving force for compound development, for example ELQ-300, a new pre-clinical candidate that works by inhibiting the well-known antimalarial target cytochrome bc 1 [230] . However, new structures of established targets continue to be determined, and in this section of the present review we aim to give an overview of some of the recently determined structures of antimalarial targets.
TrxR (thioredoxin reductase)
The malarial parasite possesses a network of enzymes whose role is to protect against oxidative stress, particularly within erythrocytes. TrxR is part of this network, and is essential to parasite survival [231, 232] . Potent inhibitors of TrxR possessing antimalarial activity have been identified [233] , but the only structural information for inhibitor design was obtained from models of Pf TrxR based on the human and mouse protein structures [234, 235] . Boumis et al. [236] have now determined the structure of Pf TrxR and compared it with the human orthologue. They identified major differences between the models and the crystal structure, particularly close to and within the dimer interface, where a key pocket differs in terms of both size and character to the human protein. This pocket is proposed to be the binding site for the previously identified inhibitors [233] ; however, confirmation by structural characterization of compound binding is required.
Atg8-Atg3 interaction
Autophagy is crucial to microneme disposal in the Plasmodium liver stage, and Atg8, whose interaction with Atg3 has been implicated in autophagy, is essential for parasite survival. Targeting this interaction could therefore generate antimalarials with a novel mode of action against the liver stage of the infection [237, 238] . Hain et al. [239] recently mapped the Atg8-Atg3 interaction surface with a detailed mutational analysis, designed a seven-residue peptide capable of mimicking Atg3 in the interaction and solved the crystal structure of the resulting complex. This structural information, together with knowledge of a lead-like fragment inhibitor of the Atg8-Atg3 interaction identified in the same study (1,2,3-trihydroxybenzene), suggests that a SBDD programme is likely to follow.
Arginase
Inhibitors of arginase, which catalyses the hydrolysis of L-arginine to form L-ornithine and urea, are of interest to treat a variety of human conditions, and have been determined to possess antimalarial activity [240] . Whereas the antimalarial mechanism of action is largely unknown, malarial parasites with arg − variants show decreased liver infectivity, which suggests that inhibitors of this enzyme could be active against the liver stage of the Plasmodium life cycle [240] . The structure of P. falciparum arginase bound to compounds has been used to inform the design of potent human arginase inhibitors [240, 241] , and, although this means that current inhibitors are non-specific, they can be used for target validation and a potential starting point for further P. falciparum arginase-specific inhibitor development.
MetAP (methionine aminopeptidase) 1b
The MetAPs perform the essential housekeeping role of catalysing the removal of the N-terminal initiator methionine during protein synthesis [242] . There are four MetAP enzymes in P. falciparum (MetAP1a-MetAP1c and MetAP2). Inhibition of Pf MetAP1b with the highly selective compound XC11, that contains a 2-(2-pyridinyl)-pyrimidine core, resulted in inhibition of P. falciparum proliferation in vitro and was active in mouse malaria models that included drug-resistant P. falciparum strains [243] . The structure of Pf MetAP1b has been solved (PDB code 3S6B), opening the way for SBDD.
Hits before targets: identification of unknown antimalarial targets
Whole-cell screens are identifying increasing numbers of hit compounds, yet, without knowledge of the target proteins, compound optimization can stall rapidly. An elegant comparative genomics method of target identification was used to identify P. falciparum lysRS (lysyl-tRNA synthetase) as the target of cladosporin, a hit from a phenotypic whole-cell screen of a natural product library with an unknown mechanism of action [244] . The approach involves inducing parasite resistance to the hit compound and subsequently comparing the genome of the resistant strain with that of its ancestors to identify mutated protein(s) [245] [246] [247] [248] . LysRS acts as part of the protein translation machinery by attaching lysine residues to tRNA molecules before insertion into proteins [249, 250] . In addition to identifying lysRS as a target for antimalarial development, Hoepfner et al. [244] generated a structural model based on the equivalent yeast and human proteins to probe features that could be exploited to design selective Pf lysRS inhibitors. However, the crystal structure of Pf lysRS had since been determined, providing the means for a SBDD programme [251] .
Fumarranol, a derivative of the natural fumagillin compound, was shown to inhibit growth of CQ-sensitive and -resistant strains of P. falciparum, and showed antiparasitic activity in a mouse model [252] . Fumarranol was determined to target Pf MetAP2 with high selectivity [252] . To date, there are no structures of Pf MetAP2; however, structures of enzymes from human and hyperthermophiles are available.
Structures before targets: structural determination of potential antimalarial targets
The advent of structural genomics programmes brought about a shift from traditional studies that characterized the function of a protein before determination of its structure to using a proteins structure to inform on its function. This approach has affected the field of drug discovery, providing the crystal structures of potential targets before any functional validation of that protein as a target. Early availability of a protein structure can accelerate compound discovery and optimization by allowing the 'druggability' of the target to be characterized (such as potential small-moleculebinding pockets or -binding site similarity to human homologues), and rapid determination of ligand-bound structures when binders become available.
The crystal structures of a number of targets that qualify as potential antimalarial targets have recently been determined. Although we do not intend to provide a detailed review of these potential SBDD targets here, they include P. falciparum 3-phosphoglycerate kinase, which is essential to the glycolytic pathway. The P. falciparum 3-phosphoglycerate kinase was characterized as a two-domain structure joined by a flexible helix which mediates domain motions to bring two substratebinding sites into close proximity for catalysis [253] . Wrenger et al. [254] have solved the structure of P. falciparum aspartate aminotransferase, a key enzyme in nitrogen metabolism, with an active site highly conserved between organisms. However, the crystal structure allowed the authors to identify potential smallmolecule interaction sites unique to the Plasmodium enzyme, and suggest that a small-molecule inhibitor that does not affect the equivalent human enzyme could be designed. Additionally, the structures of two additional P. falciparum enzymes of the MEP pathway of isoprenoid biosynthesis have recently been determined: 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase (IspF) [255] and (E)-4-hydroxy-3-methyl-but-2-enyldiphosphate reductase [256] . Finally, the structure of the catalytic domain of P. falciparum tryptophanyl-tRNA synthetase, responsible for the activation of tryptophan amino acids during protein translation, has been determined [257] . Given that P. falciparum lysRS was determined to be the target of a hit from a whole-cell phenotypic screen (described above), P. falciparum tryptophanyl-tRNA synthetase may also prove to be a valid antimalarial target.
Structural genomics programmes have been established to specifically investigate malarial proteins of potential therapeutic interest. The SGC (Structural Genomics Consortium) [258] (http://www.thesgc.org/) and MSGPP (Medical Structural Genomics of Pathogenic Protozoa) (http://www.msgpp.org/) both have dedicated programmes for determining the crystal structures of essential malarial proteins, and, since they were established, have together deposited in the PDB over 150 structures of P. falciparum and P. vivax proteins. Although some of these structures have been the target of further investigation and publication (for example, [258] [259] [260] [261] [262] [263] [264] [265] [266] ), most have no functional information available. Both consortia have also established pathways directly into analysis of small-molecule binding, and have formed the basis for SBDD projects discussed in the present review [145, 259, 260] , demonstrating the validity of the approach to the identification of potential new antimalarial targets.
SBDD AND LEAD TO MEDICINE
We have discussed in detail current antimalarial SBDD programmes that are making progress in the development of new lead molecules. However, there are a range of considerations that need to be addressed for any lead molecule in its development first to clinical candidate and then to new medicine. The MMV impose strict restrictions on novel antimalarial medicines, and Burrows et al. [267] have recently outlined the introduction of target candidate profiles, which describe the characteristics required for a successful clinical candidate, in terms of (i) clinical safety and efficacy, (ii) cost management, and (iii) potential for development of resistance. Although, traditionally, SBDD has predominantly worked as a separate (and largely in vitro) entity focused on designing compounds of high potency and selectivity against a single Plasmodium species, if the field is to successfully address the stringent requirements for a novel antimalarial compound, SBDD programmes need to continue to evolve. Modern SBDD projects need to be conducted in close association with in vivo validation methods across multiple Plasmodium species, and with continual consideration of the ADME (absorption, distribution, metabolism and excretion), pharmacokinetic and pharmacodynamic properties of the designed series to avoid high attrition rates during late stages of development. The traditional emphasis on selectivity and potency remains vital for minimizing off-target effects and dosage (thereby reducing cost), but considerations such as ease of synthesis and production cannot be ignored. Finally, our understanding of multidrugresistant diseases has come a long way since early antimalarial agents were developed; novel approaches to combating resistance need to be explored to avoid future malarial defences. Indeed, the expansion of many SBDD programmes to address these issues is evident in the projects discussed in the present review, particularly in terms of early in vivo validation (Table 1) , targeting multiple Plasmodium species (such as the NMT, AMA1 and SUB1 inhibition series) and consideration of future resistance development (such as for DHFR-TS).
CONCLUSION
There is an urgent need for novel antimalarial agents to combat the global threat of malaria. An open access understanding has catalysed collaborative worldwide research efforts to develop the necessary range of new and effective antimalarial agents. In the fight against malaria, SBDD is a valuable instrument, providing a means to elucidate the role various proteins play in parasite processes, and target these processes for therapeutic intervention. Within a drug discovery programme, structural biology can be used to characterize a target protein, identify hit compounds, accelerate optimization of these hits to leads, and inform strategies to prevent the development of parasite resistance. However, in addition to the traditional targets of high potency and selectivity, if candidates from SBDD programmes are to succeed in the clinic and in the field, we must place an emphasis on additional compound characteristics such as their pharmacokinetic and pharmacodynamic profiles, any off-target toxicity, and ease/cost of compound manufacture. Regardless, SBDD has done, and will continue to, play a valuable role in the discovery of novel antimalarial agents. Developing a novel range of compounds effective against malaria is a demanding undertaking; however, with improvements in technologies continually enhancing our understanding of the disease and fuelling drug discovery efforts, new weapons against the malarial parasite are attainable. 
